S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Zoetis Stock Price, News & Analysis (NYSE:ZTS)

$179.65
-2.47 (-1.36%)
(As of 12/5/2023 ET)
Compare
Today's Range
$178.86
$182.04
50-Day Range
$151.46
$182.12
52-Week Range
$140.76
$194.99
Volume
1.43 million shs
Average Volume
1.95 million shs
Market Capitalization
$82.48 billion
P/E Ratio
36.51
Dividend Yield
0.83%
Price Target
$216.29

Zoetis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
20.4% Upside
$216.29 Price Target
Short Interest
Healthy
0.66% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-4.66
Upright™ Environmental Score
News Sentiment
1.53mentions of Zoetis in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$4.57 M Sold Last Quarter
Proj. Earnings Growth
10.54%
From $5.41 to $5.98 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

100th out of 948 stocks

Pharmaceutical Preparations Industry

29th out of 421 stocks


ZTS stock logo

About Zoetis Stock (NYSE:ZTS)

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

ZTS Stock Price History

ZTS Stock News Headlines

Zoetis Inc Class A
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Expert Ratings for Zoetis
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Zoetis (NYSE:ZTS) Jumps on Q3 Beats
Zoetis Inc. (NYSE:ZTS) Q3 2023 Earnings Call Transcript
Q3 2023 Zoetis Inc Earnings Call
The Zoetis Inc (ZTS) Company: A Short SWOT Analysis
Zoetis Q3 Profit Rises; Updates FY Outlook
11 %
Zoetis (ZTS) Q3 2023 Earnings Call Transcript
Zoetis Announces Third Quarter 2023 Results
Earnings Outlook For Zoetis
Zoetis Inc Class A ZTS
Top 20 Animal Health Companies in the World
See More Headlines
Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 12/1 Dividend
10/31/2023
Last Earnings
11/02/2023
Dividend Payable
12/01/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/13/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
98978V10
Employees
13,800
Year Founded
2012

Price Target and Rating

Average Stock Price Target
$216.29
High Stock Price Target
$260.00
Low Stock Price Target
$195.00
Potential Upside/Downside
+20.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$2.11 billion
Pretax Margin
34.38%

Debt

Sales & Book Value

Annual Sales
$8.08 billion
Cash Flow
$5.94 per share
Book Value
$9.45 per share

Miscellaneous

Free Float
458,425,000
Market Cap
$82.48 billion
Optionable
Optionable
Beta
0.85

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives















ZTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Zoetis stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZTS shares.
View ZTS analyst ratings
or view top-rated stocks.

What is Zoetis' stock price target for 2024?

6 Wall Street research analysts have issued 12 month price objectives for Zoetis' shares. Their ZTS share price targets range from $195.00 to $260.00. On average, they anticipate the company's share price to reach $216.29 in the next year. This suggests a possible upside of 20.4% from the stock's current price.
View analysts price targets for ZTS
or view top-rated stocks among Wall Street analysts.

How have ZTS shares performed in 2023?

Zoetis' stock was trading at $146.55 at the beginning of 2023. Since then, ZTS shares have increased by 22.6% and is now trading at $179.65.
View the best growth stocks for 2023 here
.

When is Zoetis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our ZTS earnings forecast
.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) released its quarterly earnings results on Thursday, November, 2nd. The company reported $1.36 earnings per share for the quarter, beating analysts' consensus estimates of $1.35 by $0.01. The company had revenue of $2.15 billion for the quarter, compared to analyst estimates of $2.17 billion. Zoetis had a trailing twelve-month return on equity of 52.22% and a net margin of 27.24%.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Thursday, October 12th. Shareholders of record on Wednesday, November 1st will be paid a dividend of $0.375 per share on Friday, December 1st. This represents a $1.50 annualized dividend and a dividend yield of 0.83%. The ex-dividend date is Tuesday, October 31st.
Read our dividend analysis for ZTS
.

Is Zoetis a good dividend stock?

Zoetis (NYSE:ZTS) pays an annual dividend of $1.50 per share and currently has a dividend yield of 0.84%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 30.49%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 25.08% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZTS.

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (2.69%), Morgan Stanley (2.67%), FMR LLC (1.77%), Northern Trust Corp (1.34%), Polen Capital Management LLC (1.12%) and Bank of New York Mellon Corp (0.87%). Insiders that own company stock include Glenn David, Gregory Norden, Heidi C Chen, Kristin C Peck, Robert Edward Kelly, Robert J Polzer, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends
.

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Zoetis have any subsidiaries?
The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Limited, Abaxis Europe GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma Animal Health Company, Alpharma Animal Health Hong Kong Co. Limited, Alpharma Bermuda LLC, Alpharma Euro Holdings LLC, Alpharma Holdings Barbados SRL, Alpharma LLC, Alpharma Luxembourg S.A.R.L. y Compania Limitada, Alpharma do Brasil Ltda., Bovigen, Catapult Genetics Pty Ltd, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Fish Vet Group, Fish Vet Group Limited, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Jorox Pty, King Animal Health, Microtek International Inc, Mikjan Corporation, Nexvet, Nexvet Australia Pty Ltd, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Performance Livestock Analytics Inc., Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS., Pharmaq Analytiq AS, Pharmaq Analytiq Limited, Pharmaq Analytiq SpA, Pharmaq Fishteq AS, Pharmaq Fishteq SpA, Pharmaq Ltd, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Phoenix Lab, Platinum Performance, Platinum Performance Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics Corporation, Synbiotics LLC, Vetnex Animal Health Ltd, Virtual Recall, Virtual Recall Limited, Virtual Recall Pty Ltd, ZNLabs, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis Animal Health ApS, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark ApS, Zoetis Deutschland GmbH, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management Shanghai Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis Import Egypt LLC, Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Reference Laboratories China Co. Ltd., Zoetis Reference Labs LLC, Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa Pty Ltd., Zoetis Spain S.L., Zoetis Subsidiary Holdings Inc., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Sweden AB, Zoetis Taiwan Limited, Zoetis Thailand Limited, Zoetis Treasury Center BV, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..
Read More
This page (NYSE:ZTS) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -